Skip to content

Recently, a new oral small molecule, apremilast, has been approved for the treatment of patients with moderate-to-severe plaque psoriasis

Recently, a new oral small molecule, apremilast, has been approved for the treatment of patients with moderate-to-severe plaque psoriasis 1

OTEZLA offers an important new treatment option for patients whose symptoms are not adequately improving with their current treatments. OTEZLA is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). OTEZLA has not been studied in pregnant women or in women who are breastfeeding. Apremilast, Otezla, is an oral small molecule recently approved for the treatment of patients with moderate-to-severe plaque psoriasis. Apremilast has been approved by the USA FDA for the treatment of active psoriatic arthritis (PsA) and moderate-to-severe psoriasis (PsO). For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).

Recently, a new oral small molecule, apremilast, has been approved for the treatment of patients with moderate-to-severe plaque psoriasis 2Otezla provides a new treatment option for patients suffering from this disease. On September 23, 2014, apremilast received a new indication by the FDA for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Apremilast is a small-molecule inhibitor of PDE-4 specific for cyclic adenosine monophosphate (cAMP). Increased systemic exposure of apremilast has been observed in patients with severe renal impairment; the dose of apremilast should be reduced to 30 mg once daily in patients with severe renal impairment. Apremilast is a drug for the treatment of certain types of psoriasis and psoriatic arthritis. Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals. 6 In September 2014, the US FDA approved apremilast for the treatment of moderate to severe plaque psoriasis. In Europe, the drug is contraindicated during pregnancy because mice and monkeys receiving very high doses of apremilast have been observed to suffer miscarriages and other pregnancy problems. Advances in the understanding of psoriasis pathophysiology has led to more treatment options for dermatologists in managing patients with this skin condition. It is also approved for the treatment of adult patients with active psoriatic arthritis. 3 trials of apremilast 30 mg twice daily for moderate to severe plaque psoriasis. Tofacitinib is a small molecule that targets the JAK pathway, a signaling pathway inside the cells, thought to play a role in chronic inflammatory responses.

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Although treatment can provide patients with high degrees of disease improvement, there is no cure for psoriasis. Severe disease Severe psoriasis requires phototherapy or systemic therapies such as retinoids, methotrexate, cyclosporine, apremilast, or biologic immune modifying agents. Topical calcitriol ointment has been prescribed in Europe for years, and is now available in the United States. Update on New and Emerging Therapies in the Management of Psoriasis. Since the approval of several of these agents, other biologic agents and small molecules have been developed; some of these have been approved recently by the U. Apremilast; brodalumab; guselkumab; interleukin-17 inhibitors; Interim results through week 16 were recently presented from a phase II, multicenter, controlled trial to evaluate guselkumab in patients with moderate to severe plaque psoriasis.

Otezla (apremilast), An Oral Pde-4 Inhibitor, Receives Fda Approval For The Treatment Of Patients With Active Psoriatic Arthritis And Plaque Psoriasis

Compound/DeviceSpecialtyIndicationCompound ClassTarget Apremilast (CC-10004) Psoriatic arthritisRheumatologyPsoriatic arthritisAnti-inflammatoryImmune system Mechanism of action: CC-10004 (apremilast), a SM-inhibitor, down regulates inflammatory reactions via an orally available small molecules that inhibit the production of multiple pro inflammatory mediators including: interleukin-2 (IL-2), IL-12, interferon-gamma, TNF-alpha, leukotrienes, and nitric oxide synthase. For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). New small molecules for treatment of psoriasis. In a Phase II study of oral tofacitinib in patients with moderate-to-severe plaque psoriasis, a 75 improvement in PASI (PASI-75) response was achieved in 67 of patients treated with 15 mg orally twice daily at week 12. While many such inhibitors have been developed, their use is limited by side effects such as nausea and vomiting, reported at subtherapeutic levels. Apremilast has recently received its first approval for active psoriatic arthritis in adults in the USA. OTEZLA is the first in a new class of oral treatment for psoriasis, acting as an inhibitor of phosphodiesterase 4 (PDE4), which plays an important role in the chronic inflammation associated with the development of skin symptoms in psoriasis. This is especially good news for newly diagnosed patients with moderate to severe plaque psoriasis and also for my treatment-experienced patients. OTEZLA is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). OTEZLA has not been studied and is therefore not indicated in combination with other systemic (conventional or biologic) therapies or phototherapy for psoriasis. Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in psoriasis, psoriatic arthropathies, and Beh et’s syndrome. Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and doses of 20 mg twice daily have shown efficacy in the treatment of moderate to severe plaque psoriasis in a 12-week phase 2 study. We assessed the clinical efficacy and safety of different doses of apremilast in the treatment of patients with moderate to severe plaque psoriasis. Opens Table in new tab. Several oral and topical small molecules, spanning different therapeutic classes, are proving to be promising treatment options in psoriasis. Key Words: apremilast, baricitinib, dimethyl fumarate, fumaric acid esters, inflammation, JAK inhibitors, Janus kinases, phosphodiesterase 4 inhibitors, ponesimod, psoriasis, ruxolitinib, small molecules, sphingosine 1-phosphate receptor agonists, tofacitinib. 1,3 It has been reported to be a safe and effective therapy for ulcerative colitis4 and rheumatoid arthritis, both with and without concomitant methotrexate therapy.5,6 Tofacitinib has been approved for use in rheumatoid arthritis in the US. OD was carried out over 6 weeks in patients with moderate to severe psoriasis.

Improvements In Patient-reported Outcomes With Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In The Treatment Of Moderate To Severe Psoriasis: Results From A Phase Iib Randomized, Controlled Study

There are several forms of the disease, the most common of which is plaque psoriasis, appearing as raised, red patches covered with a white buildup of dead skin cells called plaque. Individuals with moderate to severe psoriasis may be prescribed systemic medications, pharmaceuticals that work on the entire body. This has led to a flurry of new activity in the biologic pipeline for psoriasis treatment. Already FDA-approved for psoriatic arthritis, the oral agent apremilast (Otezla, Celgene) is an inhibitor of phosphodiesterase. Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: Results from the Efficacy of Response And Safety of 2 fixed Secukinumab Regimens in Psoriasis (ERASURE), a Pivotal Phase 3 Study poster. Treatment options for moderate to severe psoriasis include topical and systemic medications, phototherapy, and excimer laser, Combination therapies are often more effective than one treatment alone. Several new agents to treat psoriasis are under study, including oral medications and injectable agents. Psoriasis has been linked to an increased risk of heart attack and cardiovascular disease. Plaque psoriasis leads to skin patches that start off in small areas, about 1/8 of an inch wide. HLA Molecules. Inc.) are in Phase III for moderate-to-severe plaque psoriasis.

Methotrexate single weekly dose (oral, subcutaneous, intramuscular) 15 mg, max 25 to 30 mg;. In addition, small studies have been published with successful therapeutic intervention using alefacept, visilizumab or anakinra, but controlled trials are needed. In clinical studies of plaque psoriasis, patients are treated with an initial 80 mg dose of adalimumab (2 40-mg injections) followed by 1 adalimumab injection (40 mg) 1 week later.